M Buckle1, A Lee2, Q Mohamed1, E Fletcher1, A Sallam1, R Healy1, I Stratton3, A Tufail2, R L Johnston1. 1. Department of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham Hospital, Cheltenham, UK. 2. Medical Retina Department, Moorfields Eye Hospital, London, UK. 3. Gloucester Diabetic Retinopathy Research Group, Cheltenham General Hospital, Cheltenham, UK.
Abstract
AIMS: This study aimed to evaluate the incidence and prevalence of blindness, sight impairment, and other visual acuity (VA) states in patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD) in Gloucestershire. METHODS: Serial VA and injection data for all treatment-naive patients receiving their first intravitreal injections of ranibizumab for nAMD in the Gloucestershire National Health Service Ophthalmology department between 2008 and 2010 were extracted from an electronic medical record system. RESULTS: The prevalence of blindness (VA in the better-seeing eye ≤25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) at the time of first intravitreal injection was 0.8%, increasing to 3.5% after 3 years. The prevalence of sight impairment (VA in the better-seeing eye 26-39 ETDRS letters) increased from 4.1% at baseline to 5.5% after 3 years. The incidence of initiating ranibizumab treatment for nAMD in people aged ≥50 years in Gloucestershire was 111 people per 100 000 population in 2009, and 97 people in 2010. The incidence of patients meeting the visual criteria for blindness and sight impairment registration from treated nAMD in people aged ≥50 years in Gloucestershire was 3.5 and 9.7 people, respectively per 100 000 population in 2010. CONCLUSION: This is the first real-world study on the incidence and prevalence of eligibility for blindness and sight impairment registration in treated nAMD in the UK based on VA data. The incidence and prevalence of eligibility for certification of blindness or sight impairment in patients treated with ranibizumab for nAMD is low in Gloucestershire, with only 3.6% of the incident population progressing to blindness in 2010.
AIMS: This study aimed to evaluate the incidence and prevalence of blindness, sight impairment, and other visual acuity (VA) states in patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD) in Gloucestershire. METHODS: Serial VA and injection data for all treatment-naive patients receiving their first intravitreal injections of ranibizumab for nAMD in the Gloucestershire National Health Service Ophthalmology department between 2008 and 2010 were extracted from an electronic medical record system. RESULTS: The prevalence of blindness (VA in the better-seeing eye ≤25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) at the time of first intravitreal injection was 0.8%, increasing to 3.5% after 3 years. The prevalence of sight impairment (VA in the better-seeing eye 26-39 ETDRS letters) increased from 4.1% at baseline to 5.5% after 3 years. The incidence of initiating ranibizumab treatment for nAMD in people aged ≥50 years in Gloucestershire was 111 people per 100 000 population in 2009, and 97 people in 2010. The incidence of patients meeting the visual criteria for blindness and sight impairment registration from treated nAMD in people aged ≥50 years in Gloucestershire was 3.5 and 9.7 people, respectively per 100 000 population in 2010. CONCLUSION: This is the first real-world study on the incidence and prevalence of eligibility for blindness and sight impairment registration in treated nAMD in the UK based on VA data. The incidence and prevalence of eligibility for certification of blindness or sight impairment in patients treated with ranibizumab for nAMD is low in Gloucestershire, with only 3.6% of the incident population progressing to blindness in 2010.
Authors: Neil M Bressler; Tom S Chang; Ivan J Suñer; Jennifer T Fine; Chantal M Dolan; James Ward; Tsontcho Ianchulev Journal: Ophthalmology Date: 2010-03-02 Impact factor: 12.079
Authors: Simon P Harding; Keith Tomlin; Barnaby C Reeves; Julia Langham; Jemma Walker; James Carpenter; Richard Grieve; William P Patton; Katherine A Muldrew; Tunde Peto; Usha Chakravarthy Journal: Ophthalmology Date: 2009-12 Impact factor: 12.079
Authors: Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili Journal: Am J Ophthalmol Date: 2003-09 Impact factor: 5.258
Authors: Dimitrios A Karagiannis; Meropi Lygerou; Georgios Papadopoulos; Stamatina A Kabanarou; Miltiadis Aspiotis; Doukas C Dardabounis; Panagiotis G Minakakis; Sofia I Spai; Chrysanthi Koutsandrea; Panagiotis Oikonomidis; Georgia N Pantelopoulou; Olga C Kousidou; Miltiadis Tsilimbaris Journal: Clin Ophthalmol Date: 2020-05-25